

AD \_\_\_\_\_

CONTRACT NUMBER DAMD17-96-C-6105

TITLE: Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin

PRINCIPAL INVESTIGATOR: Roman Perez-Soler, M.D.

CONTRACTING ORGANIZATION: The University of Texas  
M. D. Anderson Cancer Center  
Houston, Texas 77030

REPORT DATE: Ocotber 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

1990415041

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE October 1998	3. REPORT TYPE AND DATES COVERED Annual (23 Sep 97 - 22 Sep 98)	
4. TITLE AND SUBTITLE Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin		5. FUNDING NUMBERS DAMD17-96-C-6105	
6. AUTHOR(S) Roman Perez-Soler, M.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas/M.D. Anderson Cancer Center Houston, Texas 77030		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT <i>(Maximum 200 words)</i>			
<p>Nine patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 14 doses of liposomal-annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50% of patients. No antitumor responses were seen.</p>			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 7	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

✓ Where copyrighted material is quoted, permission has been obtained to use such material.

✓ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
R. P. Ley  
PI - Signature

11/3/98  
Date

## **TABLE OF CONTENTS**

Front cover	1
SF 298	2
Foreword	3
Table of Contents	4
Introduction	5
Report	5
Conclusions	7
References	7

## INTRODUCTION

Liposomal-Annamycin is a liposome entrapped new anthracycline antibiotic which has shown lack of cross-resistance in vitro and in vivo in different cell lines that express P-glycoprotein and MRP. In a Phase I study conducted in patients with solid tumors, the dose limiting toxicity was myelosuppression. No alopecia, mucositis, cardiac, skin, nor gastrointestinal toxicities were observed. The maximum tolerated dose was 210 mg/m<sup>2</sup> administered intravenously every 3 weeks. Because the multidrug resistance phenotype has been associated with some human malignancies, particularly acute leukemia and breast carcinoma, when they become refractory to standard chemotherapy, we proposed and initiated a Phase II study of liposomal-Annamycin in patients with metastatic breast carcinoma refractory to doxorubicin. This report summarizes the status of this study.

## REPORT

### ELIGIBILITY CRITERIA

1. Metastatic breast carcinoma
2. Anthracycline-resistant
3. Measurable disease
4. Life expectancy >12 weeks
5. Prior anthracycline <350 mg/m<sup>2</sup> of doxorubicin equivalent by bolus, <450 mg/m<sup>2</sup> by prolonged infusion
6. Adequate bone marrow function
7. Ejection fraction >55%

### PATIENT CHARACTERISTICS

A total of nine patients have been entered in the study and a total of 14 doses of liposomal-annamycin have been given. In four courses, the dose given was 190 mg/m<sup>2</sup>, in eight courses 210 mg/m<sup>2</sup> and in the other two courses 250 mg/m<sup>2</sup>. The following Table summarizes the characteristics of the patients entered.

Number of patients entered	9
Number of patients evaluable	9
Age median (range)	50 (34-73)
Performance status	
1	8
2	1

Sex: female	9
Race:	
Black	4
Hispanic	2
White	2
Histology	
Ductal carcinoma, invasive	9
Prior therapy	
Chemotherapy	9
Hormonal therapy	3
Radiation therapy	6
Surgical therapy	7
Prior chemotherapy: number of regimens	
1	2
2	1
3	4
4	2
number of agents	
3	1
>3	8

## TOXICITY

Toxicity has been mild and mostly limited to granulocytopenia as indicated below:

### 1. Myelosuppression

Dose	No courses	Granulocyte nadir (range) (day)	Platelet nadir (range) (day)
190mg/m <sup>2</sup>	4	1.2 (0.7-1.8) 11	192 (134-251) 14
210	8	1.5 (0.5-3.0) 15	218 (145-288) 10
250	2	0.8 (0.3-1.3) 11	169 (146-192) 8

---

## 2. Non-hematological toxicities

Nausea and vomiting was observed after 6 courses (grade 3 in one, grade 2 in two, and grade 1 in three). Diarrhea grade 1 was observed after one course. Stomatitis was observed after 4 courses (grade 2 in two, and grade 1 in two). One grade 1 allergic reaction was observed.

## **ANTITUMOR ACTIVITY**

Eight patients progressed after 1 or 2 cycles of liposomal-annamycin. One patients remained stable after 2 cycles of liposomal-annamycin. No tumor responses have been seen so far.

## **CORRELATIVE TISSUE STUDIES**

Three tissue specimens were obtained pre-therapy for MDR analysis. These samples are kept frozen in Dr. Sahin's laboratory and will be assayed when the study is completed and/or responses are seen.

## **CONCLUSIONS**

Results obtained to date suggest that liposomal-annamycin is very well tolerated with grade 3 granulocytopenia being observed in a minority of patients. Non-hematological toxicity is minimal.

No tumor responses have been observed so far.

The study will continue to complete fourteen fully evaluable patients. Baseline tumor biopsies will be obtained if possible to analize MDR status. If no responses are seen in this cohort of 14 patients, the study will be closed and another Phase II study in patients not anthracycline refractory will be initiated.

## **REFERENCES**

1. Booser D, Zou Y, Priebe W, Perez-Soler R. Phase I clinical and pharmacology study of liposomal-annamycin. In preparation for submission to Clinical Cancer Research.
2. Booser D, Esparza-Guerra L, Zou Y, Priebe W, Perez-Soler R. Liposomal-annamycin. Phase I clinical and pharmacological study. Proceed. ASCO 16:762 p217a, 1997.